Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Setbacks, Confidence Grows In Likely Success For Sarepta’s Duchenne Gene Therapy

Contrasts With Pfizer Safety Concerns

Executive Summary

CEO tells J.P. Morgan conference that he is confident the pivotal EMBARK study can be completed in 2022 with regulatory filing in 2023.

You may also be interested in...



The Top Five (Non-COVID) Pharma Stories Of 2021

The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.

Spotlight On High Doses Again After Pfizer Duchenne Gene Therapy Death

The death in Pfizer’s Phase I study could reflect wider safety issues for AAV-based gene therapy and could spur intervention from regulators in 2022.

Sarepta Sinks On Mixed DMD Gene Therapy Study

Any time advantage Sarepta's Duchenne muscular dystrophy gene therapy may have had over rivals, notably Pfizer, has disappeared after SRP-9001 failed to significantly improve muscle function in a closely watched trial.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel